Maio M, Pinto A, Carbone A, Zagonel V, Gloghini A, Marotta G, Cirillo D, Colombatti A, Ferrara F, Del Vecchio L
Division of Experimental Oncology 2, CRO Aviano, Italy.
Blood. 1990 Aug 15;76(4):783-90.
Indirect immunofluorescence staining with monoclonal antibody (MoAb) CL203.4 of malignant cells from 269 patients with hematologic malignancies showed a heterogeneous expression of CD54/intercellular adhesion molecule-1 (ICAM-1). This marker was expressed by malignant cells of 57 out of 118 patients with myeloid malignancies and 69 out of 135 with B-lymphoid malignancies. On the other hand, CD54 was not detected on malignant cells of 16 patients with T-lymphoid malignancies. In myeloid malignancies, CD54 is preferentially expressed by "stem cell-derived" malignancies, being detectable on blast cells from almost all patients affected by chronic myelogenous leukemia in blast phase or myelodysplastic syndromes and by only 34% of patients with de novo acute myeloid leukemia (AML). The expression of CD54 did not correlate with any specific myeloid FAB subtype, although three cases of highly undifferentiated AML (FAB MO) displayed maximal levels of the antigen. The expression of CD54 in AML was significantly associated with that of CD34 and HLA-DR antigens. In B-lymphoid malignancies, CD54 expression appears to correlate with the differentiation stage of malignant cells, since B-origin acute lymphoblastic leukemias and conventional B-chronic lymphocytic leukemias (B-CLL; ie, "dim SIg" CLL) expressed lower levels of CD54 than more mature lymphoproliferative disorders ("bright SIg" CLL, prolymphocytic leukemias, and lymphoplasmacytic tumors). "High-grade" B-cell non-Hodgkin's lymphomas (B-NHL) express in general a higher level of CD54 than "low-grade" ones. This finding in conjunction with the expression of CD54 in all 17 patients with "bright SIg" CLL investigated (characterized by marked organomegaly and poor prognosis) suggest that the differential expression of CD54 in lymphoproliferative disorders may also relate to their degree of malignancy.
用单克隆抗体（MoAb）CL203.4对269例血液系统恶性肿瘤患者的恶性细胞进行间接免疫荧光染色，结果显示CD54/细胞间黏附分子-1（ICAM-1）表达不均一。118例髓系恶性肿瘤患者中有57例的恶性细胞表达该标志物，135例B淋巴细胞恶性肿瘤患者中有69例表达。另一方面，16例T淋巴细胞恶性肿瘤患者的恶性细胞未检测到CD54。在髓系恶性肿瘤中，CD54在“干细胞来源”的恶性肿瘤中优先表达，在几乎所有处于急变期的慢性髓性白血病或骨髓增生异常综合征患者的原始细胞中均可检测到，而初发急性髓系白血病（AML）患者中只有34%可检测到。CD54的表达与任何特定的髓系FAB亚型均无相关性，尽管3例高度未分化的AML（FAB MO）显示该抗原水平最高。AML中CD54的表达与CD34和HLA-DR抗原的表达显著相关。在B淋巴细胞恶性肿瘤中，CD54表达似乎与恶性细胞的分化阶段相关，因为B起源的急性淋巴细胞白血病和传统的B慢性淋巴细胞白血病（B-CLL；即“弱表达表面免疫球蛋白”的CLL）表达的CD54水平低于更成熟的淋巴增殖性疾病（“强表达表面免疫球蛋白”的CLL、原淋巴细胞白血病和淋巴浆细胞瘤）。“高级别”B细胞非霍奇金淋巴瘤（B-NHL）总体上比“低级别”的表达更高水平的CD54。这一发现与17例被研究的“强表达表面免疫球蛋白”CLL患者（其特征为明显的器官肿大和预后不良）中CD54的表达情况相结合，提示CD54在淋巴增殖性疾病中的差异表达可能也与其恶性程度有关。
